Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.46 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 6/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.41 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787236 | 0.72 | APP (0.52) | IP6K1IP6K3IP6K2APPGRM5 | |
| SCHEMBL11932672 | 0.71 | MKNK1 (0.46) | — | |
| SCHEMBL2114741 | 0.69 | APP (0.92) | APPGRM5MAPTHNF4A | |
| Diphenylacetylene SCHEMBL27628902 | 0.69 | APP (0.92) | APPGRM5MAPTASIC3HNF4A | |
| SCHEMBL12722831 | 0.68 | MKNK1 (0.44) | — | |
| SCHEMBL13330735 | 0.68 | MKNK1 (0.40) | — | |
| SCHEMBL2620733 | 0.68 | GRM5 (0.54) | IP6K1IP6K3IP6K2APPGRM5 | |
| SCHEMBL18674393 | 0.68 | GRM5 (0.49) | GRM5 | |
| SCHEMBL713323 | 0.67 | L3MBTL1 (0.52) | MAPT | |
| SCHEMBL6364777 | 0.67 | APP (0.75) | APPGRM5MAPTASIC3HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353065-B2 | Heterocyclic bridged biphenyls | BASF SE (DE) | 2016-05-31 | — | — | US | disclosed |
| US-9353065-B2 | Heterocyclic bridged biphenyls | BASF SE (DE) | 2016-05-31 | — | — | US | disclosed |
| EP-2125752-B1 | HETEROCYCLIC BRIDGED BIPHENYLS | BASF SE (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20100109514-A1 | HETEROCYCLIC BRIDGED BIPHENYLS | UDC IRELAND LIMITED (IE) | 2010-05-06 | — | — | US | disclosed |
| US-20100109514-A1 | HETEROCYCLIC BRIDGED BIPHENYLS | UDC IRELAND LIMITED (IE) | 2010-05-06 | — | — | US | disclosed |
| WO-2008119666-A1 | HETEROCYCLIC BRIDGED BIPHENYLS | BASF SE (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100109514-A1 | HETEROCYCLIC BRIDGED BIPHENYLS | OCIAD1, SBDS, OCIAD2 | IP6K1 1212/4885IP6K3 1890/4885IP6K2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.